We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CONMED Corporation (CNMD - Free Report) delivered adjusted earnings per share (EPS) of 98 cents in the second quarter of 2024, which beat the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line improved 18.1% from the year-ago quarter’s level.
GAAP EPS for the quarter was 96 cents compared with 43 cents per share in the year-ago period.
The company’s shares have lost 14.7% in the past six months against the industry’s rise of 1.5%. The broader S&P 500 Index has gained 11.7% in the same time frame.
Image Source: Zacks Investment Research
Revenues in Detail
CONMED’s revenues totaled $332.1 million, up 4.5% year over year. The top line missed the Zacks Consensus Estimate by 0.7%. At constant exchange rate (CER), revenues increased 5.2%.
CNMD’s second-quarter sales were driven by strong growth in the United States as well as international markets. The second quarter witnessed steady surgical volumes. The performance of CONMED’s BioBrace in the foot and ankle space seemed encouraging.
Segmental Details
Revenues in the Orthopedic Surgery segment totaled $139.5 million, down 0.9% from the year-ago quarter’s level on a reported basis. At CER, revenues decreased 0.1%.
Sales declined 0.4% on a reported basis in the United States. Sales decreased 1.2% (up 0.1% at CER) from the prior-year quarter’s level in the international markets.
Revenues in the General Surgery segment amounted to $192.6 million, up 8.9% year over year on a reported basis and 9.4% at CER. U.S. sales increased 8.9% year over year. International sales improved 8.8% on a reported basis (10.5% at CER).
Sales by Geography
Sales in the United States totaled $185.4 million, up 6.1% year over year. International sales amounted to $146.7 million, up 2.6% year over year on a reported basis and 4% at CER.
Margins
CONMED’s gross profit improved 7.6% to $183.7 million. The gross margin improved 160 basis points to 55.3%.
Selling & administrative expenses decreased 5.5% to $122.5 million. Research and development expenses rose 3.9% year over year to $14.1 million.
The company recorded an operating income of $47.1 million compared with $27.4 million in the prior year quarter. The operating margin was 14.2%, up 560 basis points.
2024 Guidance Revised
CONMED lowered its revenue and earnings guidance for 2024 based on incremental foreign currency headwinds.
The company expects revenues between $1.305 billion and $1.315 billion for 2024 compared with the prior guidance of $1.330 billion and $1.355 billion. The Zacks Consensus Estimate is currently pegged at $1.34 billion.
Adjusted EPS is expected to be in the range of $3.95 to $4.02 compared with the prior guided range of $4.25 to $4.35. The Zacks Consensus Estimate is currently pegged at $4.30.
Our Take
CONMED exited the second quarter of 2024 on a mixed note, wherein earnings beat the Zacks Consensus Estimate, but revenues missed the same. The second quarter witnessed the impact of supply-chain issues, primarily for the sports medicine and foot and ankle businesses within the Orthopedic segment. The issue is likely to continue, which is reflected in the company’s lowered outlook for 2024.
However, healthy demand in the General Surgery business is likely to help offset supply-chain issues hurting Orthopedic sales. The company’s early-phase new surgical robot, AirSeal, demonstrated faster growth compared to last year, and the trend is likely to continue in the second half of 2024.
CONMED Corporation Price, Consensus and EPS Surprise
Some better-ranked stocks in the broader medical space are Universal Health Service (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and ABM Industries (ABM - Free Report) . While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Service has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the industry's 34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the industry’s 10.2% rise
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% so far this year compared with the industry’s 11.9% increase
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
CONMED Corporation (CNMD - Free Report) delivered adjusted earnings per share (EPS) of 98 cents in the second quarter of 2024, which beat the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line improved 18.1% from the year-ago quarter’s level.
GAAP EPS for the quarter was 96 cents compared with 43 cents per share in the year-ago period.
The company’s shares have lost 14.7% in the past six months against the industry’s rise of 1.5%. The broader S&P 500 Index has gained 11.7% in the same time frame.
Image Source: Zacks Investment Research
Revenues in Detail
CONMED’s revenues totaled $332.1 million, up 4.5% year over year. The top line missed the Zacks Consensus Estimate by 0.7%. At constant exchange rate (CER), revenues increased 5.2%.
CNMD’s second-quarter sales were driven by strong growth in the United States as well as international markets. The second quarter witnessed steady surgical volumes. The performance of CONMED’s BioBrace in the foot and ankle space seemed encouraging.
Segmental Details
Revenues in the Orthopedic Surgery segment totaled $139.5 million, down 0.9% from the year-ago quarter’s level on a reported basis. At CER, revenues decreased 0.1%.
Sales declined 0.4% on a reported basis in the United States. Sales decreased 1.2% (up 0.1% at CER) from the prior-year quarter’s level in the international markets.
Revenues in the General Surgery segment amounted to $192.6 million, up 8.9% year over year on a reported basis and 9.4% at CER. U.S. sales increased 8.9% year over year. International sales improved 8.8% on a reported basis (10.5% at CER).
Sales by Geography
Sales in the United States totaled $185.4 million, up 6.1% year over year. International sales amounted to $146.7 million, up 2.6% year over year on a reported basis and 4% at CER.
Margins
CONMED’s gross profit improved 7.6% to $183.7 million. The gross margin improved 160 basis points to 55.3%.
Selling & administrative expenses decreased 5.5% to $122.5 million. Research and development expenses rose 3.9% year over year to $14.1 million.
The company recorded an operating income of $47.1 million compared with $27.4 million in the prior year quarter. The operating margin was 14.2%, up 560 basis points.
2024 Guidance Revised
CONMED lowered its revenue and earnings guidance for 2024 based on incremental foreign currency headwinds.
The company expects revenues between $1.305 billion and $1.315 billion for 2024 compared with the prior guidance of $1.330 billion and $1.355 billion. The Zacks Consensus Estimate is currently pegged at $1.34 billion.
Adjusted EPS is expected to be in the range of $3.95 to $4.02 compared with the prior guided range of $4.25 to $4.35. The Zacks Consensus Estimate is currently pegged at $4.30.
Our Take
CONMED exited the second quarter of 2024 on a mixed note, wherein earnings beat the Zacks Consensus Estimate, but revenues missed the same. The second quarter witnessed the impact of supply-chain issues, primarily for the sports medicine and foot and ankle businesses within the Orthopedic segment. The issue is likely to continue, which is reflected in the company’s lowered outlook for 2024.
However, healthy demand in the General Surgery business is likely to help offset supply-chain issues hurting Orthopedic sales. The company’s early-phase new surgical robot, AirSeal, demonstrated faster growth compared to last year, and the trend is likely to continue in the second half of 2024.
CONMED Corporation Price, Consensus and EPS Surprise
CONMED Corporation price-consensus-eps-surprise-chart | CONMED Corporation Quote
Zacks Rank and Stocks to Consider
Currently, CONMED carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Universal Health Service (UHS - Free Report) , Quest Diagnostics (DGX - Free Report) and ABM Industries (ABM - Free Report) . While Universal Health Service sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Universal Health Service has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 41.1% compared with the industry's 34.8% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 3.7% so far this year compared with the industry’s 10.2% rise
ABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.
ABM's shares have risen 24.1% so far this year compared with the industry’s 11.9% increase